DaVita Inc. (NYSE:DVA) Shares Acquired by Financial Strategies Group Inc.

Financial Strategies Group Inc. increased its holdings in shares of DaVita Inc. (NYSE:DVA) by 19.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 3,135 shares of the company’s stock after buying an additional 504 shares during the period. Financial Strategies Group Inc.’s holdings in DaVita were worth $507,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Harvard Management Co. Inc. acquired a new position in shares of DaVita during the second quarter valued at $55,115,000. Lazard Asset Management LLC grew its position in DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after purchasing an additional 153,008 shares during the last quarter. Andra AP fonden increased its stake in shares of DaVita by 9.0% in the second quarter. Andra AP fonden now owns 192,300 shares of the company’s stock valued at $26,647,000 after purchasing an additional 15,800 shares during the period. abrdn plc raised its holdings in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after buying an additional 2,180 shares during the last quarter. Finally, Jupiter Asset Management Ltd. boosted its position in shares of DaVita by 146.7% during the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after buying an additional 111,311 shares during the period. Institutional investors own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at approximately $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock valued at $27,387,069 in the last three months. 2.00% of the stock is currently owned by corporate insiders.

DaVita Price Performance

Shares of NYSE DVA opened at $150.37 on Friday. DaVita Inc. has a twelve month low of $82.18 and a twelve month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a 50-day moving average of $157.17 and a two-hundred day moving average of $146.59. The company has a market capitalization of $12.33 billion, a price-to-earnings ratio of 16.22, a PEG ratio of 0.83 and a beta of 0.89.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.85 earnings per share. As a group, analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. TD Cowen upped their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Finally, Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.